| Followers | 0 |
| Posts | 1357 |
| Boards Moderated | 0 |
| Alias Born | 03/20/2022 |
Tuesday, September 13, 2022 11:05:27 AM
Totally agree.
News alone of an eua application should easily propel revive past that ""paltry"" sum imo.
$5 is a massive discount for this company if what we believe buccy does is indeed true, and even more so if it includes efficacy in treating long covid.
Hope that $5 rumour is some kind of joke honestly.
News alone of an eua application should easily propel revive past that ""paltry"" sum imo.
$5 is a massive discount for this company if what we believe buccy does is indeed true, and even more so if it includes efficacy in treating long covid.
Hope that $5 rumour is some kind of joke honestly.
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
